CMS to Negotiate Medicaid Outcomes-Based Agreements for Sickle Cell Gene Therapies
The Centers for Medicare and Medicaid Services will enter talks with manufacturers to come up with a pricing and rebate scheme that will tie the gene therapies’ cost with their effectiveness.
CMS to Negotiate Medicaid Outcomes-Based Agreements for Sickle Cell Gene Therapies Read More »
